Kentaro Hayashi

Dr. Kentaro Hayashi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2023 in Burns
Verified
Journal Article
Open access
KHKentaro Hayashi
Kentaro Hayashi
YSYusuke Sasabuchi
Yusuke Sasabuchi
HMHiroki Matsui
Hiroki Matsui
MNMikio Nakajima
Mikio Nakajima
MOMasayuki Otawara
Masayuki Otawara
HYHideo Yasunaga
Hideo Yasunaga
The present study aimed to investigate the appropriate timing of excision or skin grafting of burn wounds in patients with severe burns. We retrospectively analyzed data from the Diagnosis Procedure Combination Database, a nationwide inpatient database in Japan. Patients with severe burns (burn index ≥10) who underwent excision or skin grafting within 7 days from September 2010 to March 2019 were included. We defined the early surgery group as patients who underwent excision or skin grafting within 2 days of admission and the delayed surgery group as those who underwent surgery within 3-7 days of admission. Propensity score matching was used to compare the in-hospital mortality between the two groups, yielding a cohort of 389 pairs. A total of 2362 eligible patients were categorized into the early surgery group (n = 626) and delayed surgery group (n = 1736). The overall in-hospital mortality was 19.6%. In-hospital mortality did not differ significantly between the early surgery (15.9%) and the delayed surgery groups (17.2%; p = 0.70). These results suggest that excision or skin grafting within 2 days of admission was not associated with improved in-hospital mortality compared with surgery thereafter for patients with severe burns.

15 January 2020 in Blood Purification
Verified
Journal Article
Closed access
PDF file
KHKentaro Hayashi
Kentaro Hayashi
YSYusuke Sasabuchi
Yusuke Sasabuchi
HMHiroki Matsui
Hiroki Matsui
MNMikio Nakajima
Mikio Nakajima
HOHiroyuki Ohbe
Hiroyuki Ohbe
HYHideo Yasunaga
Hideo Yasunaga
Introduction: Sepsis is a systemic inflammatory response syndrome caused by infectious diseases, with cytokines possibly having an important role in the disease mechanism. Acrylonitrile-co-methallyl sulfonate surface-treated (AN69ST) membrane is expected to improve the outcomes of patients with sepsis through cytokine adsorption. Objective: This study aimed to investigate the clinical effect of the AN69ST membrane in comparison to standard continuous renal replacement therapy (CRRT) membranes for panperitonitis due to lower gastrointestinal perforation. Methods: Using the Diagnosis Procedure Combination database, we identified adult patients with sepsis due to panperitonitis receiving any CRRT. Propensity score matching was used to compare patients who received CRRT with the AN69ST membrane (AN69ST group) and those who received CRRT with other membranes (non-AN69ST group). The primary outcome measure was in-hospital mortality. Results: A total of 528 and 1,445 patients were included in the AN69ST group and in the non-AN69ST group, respectively. Propensity score matching resulted in 521 pairs. There was no significant difference in in-hospital mortality (32.1 vs. 35.5%; p = 0.265) and 30-day mortality (41.3 vs. 42.8%, p = 0.074) between the AN69ST group and the non-AN69ST group. Conclusion: There is no significant difference in-hospital mortality between CRRT with the AN69ST membrane and CRRT with standard CRRT membranes for panperitonitis due to lower gastrointestinal perforation. These results indicate that the AN69ST membrane is not superior to the standard CRRT membrane.

Verified
Journal Article
Open access
PDF file
KHKentaro Hayashi
Kentaro Hayashi
JKJin Kikuchi
Jin Kikuchi
HHHidekazu Hishinuma
Hidekazu Hishinuma
TNTakafumi Noguchi
Takafumi Noguchi
MZMasayoshi Zaitsu
Masayoshi Zaitsu
KWKoji Wake
Koji Wake
Background/Objectives: The impacts of the coronavirus disease 2019 (COVID-19) pandemic on patients using helicopter emergency medical services (HEMS) regarding tracheal intubation and patient management remain unclear. Thus, we aimed to investigate this matter in Japan. Methods: In this retrospective, observational study, we analyzed 2277 patients who utilized HEMS in Tochigi Prefecture during 2018–2022. We included only patients who required tracheal intubation. We categorized patients from February 2020 to January 2022 in the pandemic group and those from February 2018 to January 2020 in the control group. We compared the interval from arrival at the scene to leaving the scene (on-scene time) and secondary variables between the two groups. Results: A total of 278 eligible patients were divided into the pandemic group (n = 127) and the control group (n = 151). The on-scene time was lower during the pandemic than that before (25.64 ± 9.19 vs. 27.83 ± 8.74 min, p = 0.043). The percentage of patients using midazolam was lower (11.8% vs. 22.5%, p = 0.02) and that of patients using rocuronium bromide was higher (29.1% vs. 6.0%, p < 0.001) during the pandemic. In contrast, the type of intervention other than tracheal intubation and the type of transportation to the hospital did not differ between the groups. Conclusions: The COVID-19 pandemic was associated with changes in the mission time of and the frequency of certain drugs administered by the HEMS. However, the type of intervention and the type of transportation did not differ. Further research is needed on changes in patient prognosis and condition due to the effects of the COVID-19 pandemic.

22 September 2020 in Research Square
Verified
Preprint
Open access
PDF file
KHKentaro Hayashi
Kentaro Hayashi
YSYusuke Sasabuchi
Yusuke Sasabuchi
HMHiroki Matsui
Hiroki Matsui
MNMikio Nakajima
Mikio Nakajima
HOHiroyuki Ohbe
Hiroyuki Ohbe
HYHideo Yasunaga
Hideo Yasunaga
Background: Cytokine removal therapy is one of the available therapies for sepsis. Acrylonitrile-co-methallyl sulfonate surface-treated (AN69ST, sepXiris®) membrane has cytokine adsorption capacity and has been widely used for treating sepsis in Japan. The aim of this study was to compare the effects of continuous renal replacement therapy (CRRT) with AN69ST membrane and conventional CRRT for patients with pneumonia-associated sepsis. Methods: We conducted a retrospective cohort study using the Diagnosis Procedure Combination database, a nationwide inpatient database in Japan. We identified adult patients who were hospitalized due to pneumonia and received CRRT within 2 days of admission from September 2014 to March 2017. We included patients who received CRRT with AN69ST membrane within 2 days of admission in the treatment group (AN69ST group); those who received CRRT with other membranes within 2 days of admission were included in the control group (non-AN69ST group). Propensity score matching was used to compare in-hospital mortality between the two groups. Results: Eligible patients (n=2,393) were categorized into the AN69ST group (n=631) or the non-AN69ST group (n=1,762). The overall in-hospital mortality rate in pneumonia patients treated with CRRT was 38.9%. Propensity score matching created a matched cohort of 545 pairs of patients. The in-hospital mortality rate was significantly lower in the AN69ST group than in the non-AN69ST group (35.8 vs. 41.8%, p=0.046). Conclusion: Our data suggest that CRRT with the AN69ST membrane was associated with a significantly lower in-hospital mortality than CRRT with standard membranes among patients with pneumonia-associated sepsis.

1 March 2024 in Cureus
Verified
Journal Article
Open access
PDF file
KHKentaro Hayashi
Kentaro Hayashi
KWKoji Wake
Koji Wake
Triflumizole (TFZ) is a fungicide widely used in agriculture to prevent fungal infections of fruits and vegetables. Although it is considered safe for humans and animals, its toxicity profile in humans remains largely unexplored. Here, we describe a case where an individual experienced symptoms suggestive of intoxication after ingesting TFZ emulsion. A 70-year-old man ingested TFZ emulsion (Trifumin emulsionTM) and alcohol in an attempt to commit suicide. He developed a severe disturbance of consciousness, which was not explained by the estimated blood alcohol concentration, and experienced convulsions. We managed this patient with symptomatic treatment, temporary mechanical ventilation, and antiepileptic drugs. He subsequently recovered without any sequelae. We present the first case of acute oral intoxication with TFZ emulsion. Moreover, we review the literature on TFZ-induced organ dysfunction and discuss the possible mechanisms and management of this condition.

8 November 2022 in Artificial Organs
Verified
Journal Article
Open access
KHKentaro Hayashi
Kentaro Hayashi
YSYusuke Sasabuchi
Yusuke Sasabuchi
HMHiroki Matsui
Hiroki Matsui
MNMikio Nakajima
Mikio Nakajima
HOHiroyuki Ohbe
Hiroyuki Ohbe
HYHideo Yasunaga
Hideo Yasunaga
Background: The acrylonitrile‐co‐methallyl sulfonate surface‐treated (AN69ST) membrane has cytokine adsorption capacity and is used for treating sepsis. This study aimed to compare the effects of continuous renal replacement therapy (CRRT) using the AN69ST membrane with those of CRRT using other membranes for patients with pneumonia‐associated sepsis.Methods: This retrospective, propensity score‐matched, cohort study was based on a nationwide Japanese inpatient database. We included data from adults hospitalized with a primary diagnosis of pneumonia, who received CRRT using either the AN69ST membrane or another membrane within 2 days of admission, and who were discharged from the hospitals between September 2014, and March 2017. Propensity score matching was used to compare in‐hospital mortality between the two groups.Results: Eligible patients (N = 2393) were categorized into an AN69ST group (N = 631) and a non‐AN69ST group (N = 1762). The overall in‐hospital mortality rate was 38.9%. Among the 545 propensity‐matched patient pairs, the in‐hospital mortality rate was significantly lower in the AN69ST group than in the non‐AN69ST group (35.8 vs. 41.8%, p = 0.046).Conclusions: Among patients with pneumonia‐associated sepsis treated with CRRT, CRRT with the AN69ST membrane was associated with a significantly lower in‐hospital mortality than CRRT with standard membranes.